Trends in Pain Medication Use in Patients With Type 2 Diabetes: NHANES 2005-2018.
Document Type
Article
Publication Date
4-11-2023
Publication Title
Journal of Pain and Palliative Care Pharmacotherapy
Keywords
Pain medication use, therapeutic use, diabetes, opioids, adults
ISSN
1536-0539
Volume
37
Issue/No.
3
First Page
223
Last Page
233
Abstract
The aim of this research was to compare pain medication use trends among adults with and without type 2 diabetes in the US. This cross-sectional study used data of adults with and without (type 2) diabetes from the National Health and Nutrition Examination Survey waves 2005-2018. Use of pain medication including opioids, prescription nonsteroidal anti-inflammatory drugs, gabapentinoids, serotonin norepinephrine reuptake inhibitors, skeletal muscle relaxants, and headache treatment agents was compared by diabetes status and within select social determinants of health and clinical factors. Adults with type 2 diabetes were twice as likely to be prescribed pain medications compared to those without a diabetes diagnosis (16.2% vs 8.6%). Females and those with a history of smoking or arthritis were more likely to be on pain medications. Opioid use was the most prevalent regardless of diabetes status, and use was twice as high among those with diabetes (10.8% vs 5.5%). Patients with type 2 diabetes in the US are twice as likely to be prescribed pain medications overall as well as opioids compared with those without diabetes. Clinical guideline recommendations are necessary to find pharmacologic and nonpharmacologic nociceptive pain management specific for patients with diabetes.
NSUWorks Citation
Krichbaum, Michelle; Miransky, Neil; and Perez, Alexandra, "Trends in Pain Medication Use in Patients With Type 2 Diabetes: NHANES 2005-2018." (2023). HPD Articles. 389.
https://nsuworks.nova.edu/hpd_facarticles/389
ORCID ID
DOI
10.1080/15360288.2023.2194868
Copyright
© 2023 Taylor & Francis Group, LLC
Comments
Acknowledgments The authors thank Dr. Luigi Cubeddu, PhD, MD, Professor, Nova Southeastern University College of Pharmacy, and Dr. Ana Maria Castejon, PhD, Nova Southeastern University College of Pharmacy.